文献速递前列腺癌

患者来源激素初治前列腺癌异种移植模型揭示GRB10为雄激素受体抑制基因驱动去势抵抗性前列腺癌

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-03-12

研究利用患者来源激素初治前列腺癌异种移植模型,通过转录组分析动态观察去势后基因表达变化,发现GRB10在去势抵抗阶段显著且持续上调。GRB10敲低可抑制前列腺癌细胞增殖及AKT活性,临床数据提示其高表达与侵袭性肿瘤类型和较差治疗结局相关。

要点

  • GRB10是去势抵抗性前列腺癌的驱动基因,且在去势抵抗发生前即表达升高。
  • GRB10通过激活AKT通路促进前列腺癌细胞增殖。
  • GRB10高表达与更侵袭性肿瘤类型及较差治疗结局相关,可能成为新治疗靶点。

核心结论

  • GRB10作为去势抵抗性前列腺癌的驱动基因,靶向GRB10可能成为增强去势抵抗性前列腺癌治疗的新策略。

研究设计与样本

  • 研究利用患者来源激素初治前列腺癌异种移植模型,在宿主去势后不同时间点进行转录组表达谱分析。
  • 通过在前列腺癌细胞中敲低潜在驱动基因进行功能验证,并利用前列腺癌患者数据库数据评估临床相关性。

主要发现

  • GRB10是后者中上调最显著且最一致的基因。
  • GRB10敲低显著降低前列腺癌细胞增殖及AKT活性。
  • 临床前列腺癌样本中GRB10表达升高与更侵袭性肿瘤类型和较差患者治疗结局相关。
  • 临床队列中发现AKT活性与GRB10表达呈正相关。

临床怎么用

  • GRB10可作为去势抵抗性前列腺癌的潜在分子靶点,用于开发增强现有去势抵抗性前列腺癌治疗的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although androgen deprivation therapy is initially effective in controlling growth of hormone-naive prostate cancers (HNPCs) in patients, currently incurable castration-resistant prostate cancer (CRPC) inevitably develops. OBJECTIVE: To identify CRPC driver genes that may provide new targets to enhance CRPC therapy. DESIGN, SETTING, AND PARTICIPANTS: Patient-derived xenografts (PDXs) of HNPCs that develop CRPC following host castration were examined for changes in expression of genes at various time points after castration using transcriptome profiling analysis; particular attention was given to pre-CRPC changes in expression indicative of genes acting as potential CRPC drivers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The functionality of a potential CRPC driver was validated via its knockdown in cultured prostate cancer cells; its clinical relevance was established using data from prostate cancer patient databases. RESULTS AND LIMITATIONS: Eighty genes were found to be significantly upregulated at the CRPC stage, while seven of them also showed elevated expression prior to CRPC development. Among the latter, growth factor receptor bound protein 10 (GRB10) was the most significantly and consistently upregulated gene. Moreover, elevated GRB10 expression in clinical prostate cancer samples correlated with more aggressive tumor types and poorer patient treatment outcome. GRB10 knockdown markedly reduced prostate cancer cell proliferation and activity of AKT, a well-established CRPC mediator. A positive correlation between AKT activity and GRB10 expression was also found in clinical cohorts. CONCLUSIONS: GRB10 acts as a driver of CRPC and sensitizes androgen receptor pathway inhibitors, and hence GRB10 targeting provides a novel therapeutic strategy for the disease. PATIENT SUMMARY: Development of castration-resistant prostate cancer (CRPC) is a major problem in the management of the disease. Using state-of-the-art patient-derived hormone-naive prostate cancer xenograft models, we found and validated the growth factor receptor bound protein 10 gene as a driver of CRPC, indicating that it may be used as a new molecular target to enhance current CRPC therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hao J, Ci X, Xue H, et al. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. Eur Urol. 2018. PMID: 29544736. doi:10.1016/j.eururo.2018.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。